Tags

Type your tag names separated by a space and hit enter

Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy.
Adv Clin Exp Med. 2018 Jan; 27(1):99-103.AC

Abstract

BACKGROUND

Graves' orbitopathy (GO), also known as thyroid-associated ophthalmopathy, is characterized by dramatic tissue reactivity. Both inflammation and tissue remodeling characterize the clinical course of GO. Some data has been found regarding the association of MMPs and TIMPs in GO.

MATERIAL AND METHODS

Serum concentrations of MMP-9, MMP-2, TIMP-1, and TIMP-2 were determined by ELISA method.

OBJECTIVES

Forty-eight patients (34 females, 14 males, with median age 51.5 years) with GD and hyperthyroidism were enrolled in the study. In 28 patients, active, moderate-to-severe grade orbitopathy was diagnosed. The aim of this study was to assess the serum concentrations of MMP-2, MMP-9, TIMP-1, and TIMP-2 in patients with Graves' disease (GD), with and without GO, and their relationship with disease severity, as well as to evaluate how these concentrations change after successful treatment.

RESULTS

Median serum concentrations of MMP-2 and MMP-9 were significantly higher in all patients with GD as well as in the subgroup with GO than in the control group. Median serum concentrations of TIMP-1 and TIMP-2 were significantly higher in all patients with GD than in controls. The same significant differences were observed in the subgroups with and without GO in comparison with controls. The GO subgroup showed a significant positive correlation between the MMP-9 concentration and the serum level of TSHRAb antibodies, and a clinical activity score ≥4 according to EUGOGO.

CONCLUSIONS

In our study we found that only MMP-9 differentiates the patients with and without GO, and may be used as a marker of the disease severity in patients with this manifestation of GD.

Authors+Show Affiliations

Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland.Department of Ophthalmology, Wroclaw Medical University, Poland.Department of Ophthalmology, Wroclaw Medical University, Poland.Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland.Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland.Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland.Department of Endocrinology, Diabetology and Isotope Treatment, Wroclaw Medical University, Poland.Department of Microbiology, Wroclaw Medical University, Poland.Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland. Department of Cosmetology, Wroclaw Physiotherapy College, Poland.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29521049

Citation

Kapelko-Słowik, Katarzyna, et al. "Elevated Serum Concentrations of Metalloproteinases (MMP-2, MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Patients With Graves' Orbitopathy." Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University, vol. 27, no. 1, 2018, pp. 99-103.
Kapelko-Słowik K, Słowik M, Szaliński M, et al. Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy. Adv Clin Exp Med. 2018;27(1):99-103.
Kapelko-Słowik, K., Słowik, M., Szaliński, M., Dybko, J., Wołowiec, D., Prajs, I., Bohdanowicz-Pawlak, A., Biernat, M., & Urbaniak-Kujda, D. (2018). Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy. Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University, 27(1), 99-103. https://doi.org/10.17219/acem/68991
Kapelko-Słowik K, et al. Elevated Serum Concentrations of Metalloproteinases (MMP-2, MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Patients With Graves' Orbitopathy. Adv Clin Exp Med. 2018;27(1):99-103. PubMed PMID: 29521049.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy. AU - Kapelko-Słowik,Katarzyna, AU - Słowik,Mirosław, AU - Szaliński,Marek, AU - Dybko,Jarosław, AU - Wołowiec,Dariusz, AU - Prajs,Iwona, AU - Bohdanowicz-Pawlak,Anna, AU - Biernat,Monika, AU - Urbaniak-Kujda,Donata, PY - 2018/3/10/entrez PY - 2018/3/10/pubmed PY - 2019/6/30/medline KW - Graves’ disease KW - matrix metalloproteinases KW - orbithopathy KW - tissue inhibitors of metalloproteinases SP - 99 EP - 103 JF - Advances in clinical and experimental medicine : official organ Wroclaw Medical University JO - Adv Clin Exp Med VL - 27 IS - 1 N2 - BACKGROUND: Graves' orbitopathy (GO), also known as thyroid-associated ophthalmopathy, is characterized by dramatic tissue reactivity. Both inflammation and tissue remodeling characterize the clinical course of GO. Some data has been found regarding the association of MMPs and TIMPs in GO. MATERIAL AND METHODS: Serum concentrations of MMP-9, MMP-2, TIMP-1, and TIMP-2 were determined by ELISA method. OBJECTIVES: Forty-eight patients (34 females, 14 males, with median age 51.5 years) with GD and hyperthyroidism were enrolled in the study. In 28 patients, active, moderate-to-severe grade orbitopathy was diagnosed. The aim of this study was to assess the serum concentrations of MMP-2, MMP-9, TIMP-1, and TIMP-2 in patients with Graves' disease (GD), with and without GO, and their relationship with disease severity, as well as to evaluate how these concentrations change after successful treatment. RESULTS: Median serum concentrations of MMP-2 and MMP-9 were significantly higher in all patients with GD as well as in the subgroup with GO than in the control group. Median serum concentrations of TIMP-1 and TIMP-2 were significantly higher in all patients with GD than in controls. The same significant differences were observed in the subgroups with and without GO in comparison with controls. The GO subgroup showed a significant positive correlation between the MMP-9 concentration and the serum level of TSHRAb antibodies, and a clinical activity score ≥4 according to EUGOGO. CONCLUSIONS: In our study we found that only MMP-9 differentiates the patients with and without GO, and may be used as a marker of the disease severity in patients with this manifestation of GD. SN - 1899-5276 UR - https://www.unboundmedicine.com/medline/citation/29521049/Elevated_serum_concentrations_of_metalloproteinases__MMP_2_MMP_9__and_their_inhibitors__TIMP_1_TIMP_2__in_patients_with_Graves'_orbitopathy_ L2 - http://www.advances.am.wroc.pl/pdf/2018/27/1/99.pdf DB - PRIME DP - Unbound Medicine ER -